These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11606504)

  • 1. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers.
    García-Pagán JC; Villanueva C; Vila MC; Albillos A; Genescà J; Ruiz-Del-Arbol L; Planas R; Rodriguez M; Calleja JL; González A; Solà R; Balanzó J; Bosch J;
    Gastroenterology; 2001 Oct; 121(4):908-14. PubMed ID: 11606504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT.
    García-Pagán JC; Morillas R; Bañares R; Albillos A; Villanueva C; Vila C; Genescà J; Jimenez M; Rodriguez M; Calleja JL; Balanzó J; García-Durán F; Planas R; Bosch J;
    Hepatology; 2003 Jun; 37(6):1260-6. PubMed ID: 12774003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis.
    Merkel C; Marin R; Sacerdoti D; Donada C; Cavallarin G; Torboli P; Amodio P; Sebastianelli G; Bolognesi M; Felder M; Mazzaro C; Gatta A
    Hepatology; 2000 Feb; 31(2):324-9. PubMed ID: 10655253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites.
    Borroni G; Salerno F; Cazzaniga M; Bissoli F; Lorenzano E; Maggi A; Visentin S; Panzeri A; de Franchis R
    J Hepatol; 2002 Sep; 37(3):315-21. PubMed ID: 12175626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP).
    Merkel C; Marin R; Enzo E; Donada C; Cavallarin G; Torboli P; Amodio P; Sebastianelli G; Sacerdoti D; Felder M; Mazzaro C; Beltrame P; Gatta A
    Lancet; 1996 Dec 21-28; 348(9043):1677-81. PubMed ID: 8973428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.
    Villanueva C; Miñana J; Ortiz J; Gallego A; Soriano G; Torras X; Sáinz S; Boadas J; Cussó X; Guarner C; Balanzó J
    N Engl J Med; 2001 Aug; 345(9):647-55. PubMed ID: 11547718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices.
    Sharma P; Kumar A; Sharma BC; Sarin SK
    Aliment Pharmacol Ther; 2009 Jul; 30(1):48-60. PubMed ID: 19392862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.
    Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Bellini B; Bighin R; Gatta A
    Hepatology; 2000 Nov; 32(5):930-4. PubMed ID: 11050041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients.
    Garcia-Pagan JC; De Gottardi A; Bosch J
    Aliment Pharmacol Ther; 2008 Jul; 28(2):178-86. PubMed ID: 18462268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial.
    García-Pagán JC; Villanueva C; Albillos A; Bañares R; Morillas R; Abraldes JG; Bosch J;
    Gut; 2009 Aug; 58(8):1144-50. PubMed ID: 19218249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial.
    Junquera F; López-Talavera JC; Mearin F; Saperas E; Videla S; Armengol JR; Esteban R; Malagelada JR
    Gut; 2000 Jan; 46(1):127-32. PubMed ID: 10601068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding.
    Villanueva C; Balanzó J; Novella MT; Soriano G; Sáinz S; Torras X; Cussó X; Guarner C; Vilardell F
    N Engl J Med; 1996 Jun; 334(25):1624-9. PubMed ID: 8628357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis.
    Silva G; Segovia R; Ponce R; Backhouse C; Palma M; Roblero JP; Abadal J; Quijada C; Troncoso M; Iturriaga H
    Hepatogastroenterology; 2002; 49(47):1357-62. PubMed ID: 12239942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial.
    Romero G; Kravetz D; Argonz J; Vulcano C; Suarez A; Fassio E; Dominguez N; Bosco A; Muñoz A; Salgado P; Terg R
    Aliment Pharmacol Ther; 2006 Aug; 24(4):601-11. PubMed ID: 16827811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.
    Abecasis R; Kravetz D; Fassio E; Ameigeiras B; Garcia D; Isla R; Landeira G; Dominguez N; Romero G; Argonz J; Terg R
    Hepatology; 2003 Feb; 37(2):359-65. PubMed ID: 12540786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis.
    Angelico M; Carli L; Piat C; Gentile S; Capocaccia L
    Gastroenterology; 1997 Nov; 113(5):1632-9. PubMed ID: 9352866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
    Villanueva C; López-Balaguer JM; Aracil C; Kolle L; González B; Miñana J; Soriano G; Guarner C; Balanzó J
    J Hepatol; 2004 May; 40(5):757-65. PubMed ID: 15094222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial.
    Escorsell A; Bañares R; García-Pagán JC; Gilabert R; Moitinho E; Piqueras B; Bru C; Echenagusia A; Granados A; Bosch J
    Hepatology; 2002 Feb; 35(2):385-92. PubMed ID: 11826413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices.
    Gluud LL; Langholz E; Krag A
    Aliment Pharmacol Ther; 2010 Oct; 32(7):859-71. PubMed ID: 20839387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations.
    Kravetz D
    J Clin Gastroenterol; 2007; 41 Suppl 3():S318-22. PubMed ID: 17975483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.